DNTH vs RCUS
DNTH: Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and inflammatory diseases. RCUS: A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials.
Side-by-side fundamentals
| Metric | DNTH | RCUS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $102.76 | $29.97 | |
| Market cap as of 2026-07-23 | $5.7B | $3.7B | |
| PEG as of 2026-07-23 | -0.59 | n/a | |
| Net margin as of 2026-07-23 | -12998.5% | -156.4% | RCUS higher |
| Operating margin as of 2026-07-23 | -14318.0% | -168.6% | RCUS higher |
| ROE as of 2026-07-23 | -27.3% | -69.0% | DNTH higher |
| ROA as of 2026-07-23 | -25.9% | -35.3% | DNTH higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.19 | DNTH lower |
| Revenue growth (YoY) as of 2026-07-23 | -79.5% | -15.1% | RCUS higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -4.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.75 | 0.81 | |
| 1-year return as of 2026-07-22 close | +409.7% | +218.4% | DNTH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.